Thomasville National Bank Has $286,000 Holdings in Novartis AG (NYSE:NVS)

Thomasville National Bank reduced its position in shares of Novartis AG (NYSE:NVS) by 11.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 2,944 shares of the company’s stock after selling 380 shares during the quarter. Thomasville National Bank’s holdings in Novartis were worth $286,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in NVS. Dimensional Fund Advisors LP raised its position in shares of Novartis by 23.1% in the second quarter. Dimensional Fund Advisors LP now owns 7,407,692 shares of the company’s stock valued at $788,626,000 after buying an additional 1,389,610 shares in the last quarter. Fisher Asset Management LLC lifted its position in Novartis by 15.7% during the third quarter. Fisher Asset Management LLC now owns 1,706,009 shares of the company’s stock worth $196,225,000 after purchasing an additional 231,851 shares during the period. FMR LLC grew its stake in Novartis by 5.5% during the third quarter. FMR LLC now owns 1,353,412 shares of the company’s stock worth $155,669,000 after buying an additional 70,314 shares in the last quarter. Natixis Advisors LLC increased its holdings in Novartis by 2.9% in the 3rd quarter. Natixis Advisors LLC now owns 938,844 shares of the company’s stock valued at $107,986,000 after buying an additional 26,317 shares during the period. Finally, Bank of Montreal Can raised its position in shares of Novartis by 18.7% in the 3rd quarter. Bank of Montreal Can now owns 780,980 shares of the company’s stock valued at $90,289,000 after buying an additional 123,077 shares in the last quarter. 13.12% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms recently issued reports on NVS. HSBC lowered shares of Novartis from a “hold” rating to a “reduce” rating in a research report on Wednesday, December 4th. Erste Group Bank reiterated a “hold” rating on shares of Novartis in a research note on Tuesday, November 19th. Finally, BMO Capital Markets boosted their price target on Novartis from $118.00 to $120.00 and gave the stock a “market perform” rating in a report on Wednesday, October 30th. Two equities research analysts have rated the stock with a sell rating and seven have assigned a hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and an average target price of $121.50.

Novartis Stock Up 0.1 %

Shares of NYSE:NVS opened at $99.20 on Tuesday. The company has a market capitalization of $202.76 billion, a PE ratio of 11.52, a price-to-earnings-growth ratio of 1.49 and a beta of 0.57. Novartis AG has a 52-week low of $92.35 and a 52-week high of $120.92. The company has a debt-to-equity ratio of 0.55, a quick ratio of 0.90 and a current ratio of 1.11. The company has a fifty day moving average of $101.33 and a 200-day moving average of $109.24.

Novartis (NYSE:NVS) last announced its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, beating analysts’ consensus estimates of $1.94 by $0.12. Novartis had a return on equity of 34.80% and a net margin of 35.96%. The firm had revenue of $12.82 billion for the quarter, compared to analyst estimates of $12.62 billion. During the same period last year, the firm posted $1.74 earnings per share. On average, equities analysts predict that Novartis AG will post 7.65 EPS for the current fiscal year.

Novartis Company Profile

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.